
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : Citius Oncology
Deal Size : Undisclosed
Deal Type : Agreement
Citius Expands Distribution Network for LYMPHIR with Cencora
Details : Under the agreement, Cencora will execute the distribution process of Lymphir (denileukin diftitox). It is being indicated for the treatemnt of Stage I-III cutaneous T-cell lymphoma.
Product Name : Lymphir
Product Type : Protein
Upfront Cash : Undisclosed
July 15, 2025
Lead Product(s) : Denileukin Diftitox
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : Citius Oncology
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.
Product Name : Lytenava
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Outlook Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
